Shay Capital »

Prelude Therapeutics shares owned by Shay Capital

Quarter-by-quarter ownership of Prelude Therapeutics (PRLD) shares owned by Shay Capital from 13F filings

Historical chart of Shay Capital investment in Prelude Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Prelude Therapeutics held by Shay Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prelude Therapeutics by Shay Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $144k 100k 1.44
2025-06-30 $61k 75k 0.81

More positions owned by Shay Capital

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Purecycle Technologies (PCT)
Ishares Silver Tr Ishares (SLV)
Ftai Aviation SHS (FTAI)
Vor Biopharma Com New Call Option
Sable Offshore Corp Com Shs (SOC)
First Solar (FSLR)
Tesla Motors (TSLA)
Warner Bros Discovery Com Ser A (WBD)
NVIDIA Corporation (NVDA)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Alibaba Group Hldg Sponsored Ads (BABA)
Agnc Invt Corp Com reit (AGNC)
Jd.com Spon Ads Cl A (JD)
A2z Cust2mate Solutions Corp (AZ)

View all positions for Shay Capital

Top funds holding Prelude Therapeutics

OrbiMed Advisors
Baker Bros. Advisors
Millennium Management
Vanguard Group
Renaissance Technologies
Acadian Asset Management
Morgan Stanley
BlackRock
Two Sigma Advisers
Geode Capital Management
TD Asset Management
Two Sigma Investments
Shay Capital
State Street Corporation
Goldman Sachs Group

View all funds holding Prelude Therapeutics